Rocket Pharmaceuticals, Inc.
RCKTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and. The company carries a $423.7M market cap, placing it firmly in the small-cap category. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Market Cap
$423.7M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-2.96
EPS (TTM)
$-0.18
EPS (Fwd)
$-1.30
ROE
-4.8%
ROA
-28.4%
Cash
$283.7M
Total Debt
$24.8M
Free CF
$86.1M
52W Change
12.3%
Annual Financials
Cash vs Debt
Where RCKT stands vs its 150-day and 200-day moving averages
As of the August 28, 2026 close, RCKT finished 0.28% above its 150-day moving average ($3.61) and 1.69% above its 200-day moving average ($3.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RCKT overbought or oversold?
At the August 28, 2026 close, RCKT's RSI(14) was 50.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Rocket Pharmaceuticals, Inc. holds $283.7M in cash against $24.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Annual free cash flow of $86.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -4.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
RCKT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, RCKT has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RCKT.